ALS (motor neurone disease): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TDP-43 8
• SOD1 8
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

9 of 9+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,568,130· until Sept 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spain· EU contribution €194,075· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  POLYMND: Polyamine dysregulation in Motor Neuron Disease as a targetable driver of astrocyte–neuron dysfunction

  The Chancellor Masters and Scholars of the University of Cambridge· Cambridge, United Kingdom· EU contribution €276,188· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineered Humanized Spinal Cord Construct for Advancing Health and Disease Research (SpineCraft)

  Fundacio Institut de Bioenginyeria de Catalunya· Barcelona, Spain· EU contribution €2,743,700· until Mar 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 14 running projects, newest first. Listed amounts together: €25.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Colchicine Effect on Amyotrophic Lateral Sclerosis Patients

  NCT07813858· Azienda Ospedaliero-Universitaria di Modena· Source

• Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

  NCT06856850· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 23
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 80
• Genome-Wide Association Study 24

• Clinical genome sequencing in neurodegenerative diseases-outcome in the first 500 patients.

  Hum Mol Genet, Jul 2026

• A case study of comprehensive association analysis and risk prediction of amyotrophic lateral sclerosis in a Chinese population.

  Mol Biol Rep, Jul 2026

• FLNC Complex Structural Variant Causing Distal Myopathy Identified by Family-Based Genome Sequencing.

  Am J Med Genet A, Jun 2026

• Herpesvirus genome integration in whole-genome sequences of dementia and control cohorts.

  Alzheimers Dement, Mar 2026

  Sonja W Scholz

• Sex-Specific Genetic Architecture of ALS: Evidence of a Female Protective Effect?

  Ann Neurol, Feb 2026

• Multi-omics analyses identify potential epigenetic loci associated with survival in amyotrophic lateral sclerosis across diverse populations.

  EBioMedicine, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.